Quantro: Seed capital by Evotec and Boehringer Germany’s Evotec SE and Boehringer Ingelheim Venture Fund have acquired equal minority stakes in Quantro Therapeutics GmbH, a recently established research-based biotech company based in Vienna. Evotec … more ➔
Sourcing reference productsA biosimilar is a copy version of an approved, original biological medice whose patent protection has expired. The development strategies for biosimilar product and a new biological entity (NBE) differ … more ➔
Targeting coronavirusesViennese APEIRON Biologics AG raised €17.5m to expand ongoing Phase II trials of its coronavirus-specific drug candidate APN01 in Europe to the US and Russia. The recombinant angiotensin-converting … more ➔
COVID-19: Siemens’ assay outperforms antibody tests from competitorsIn a Public England Health study, Siemens Healthineers’ COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA. more ➔
AMR: Big Pharma sets up US$1bn FundAfter leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance … more ➔
VarmX bags €32m in Series B roundLeiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push clinical development of VMX-C001, a venom-based modified recombinant Factor X. more ➔
APEIRON Biologics licences MaxCyte’s electroporation platformViennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcyte’s electroporation platform for APN401 development. more ➔
Immatics launches US$250m Nasdaq-IPOAfter closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq. more ➔
New insulin formulation allows faster blood sugar managementA new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes. more ➔
COVID-19: Lopinavir-ritonavir failedData from the UK’s RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients. more ➔
